.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,622,720

« Back to Dashboard

Details for Patent: 5,622,720

Title: Process for reducing the crystal size of ondansetron hydrochloride dihydrate
Abstract:The invention relates to a process for reducing the crystal size of ondansetron hydrochloride dihydrate produced by crystallization from solvent to a size which is suitable for effective distribution in a tablet blend, in particular 100% less that 250 .mu.m. The ondansetron hydrochloride dihydrate is desolvated by drying at elevated temperature and reduced or atmospheric pressure and is then rehydrated.
Inventor(s): Collin; David T. (Ware, GB2)
Assignee: Glaxo Group Limited (London, GB2)
Filing Date:Jun 07, 1995
Application Number:08/472,881
Claims:1. A process for reducing the crystal size of ondansetron hydrochloride dihydrate produced by crystallization from solvent, in which said ondansetron hydrochloride dihydrate is desolvated by drying at elevated temperature and reduced or atmospheric pressure and is then rehydrated, wherein the resulting crystals are suitable for homogeneous distribution in a tablet blend, said tablet providing a pharmaceutically acceptable formulation in effective amounts for treatment of ondansetron responsive conditions.

2. A process according to claim 1, in which said ondansetron hydrochloride dihydrate is prepared by crystallization from an aqueous solvent mixture.

3. A process according to claim 1, in which said ondansetron hydrochloride dihydrate is desolvated by heating at a temperature greater than 40.degree. C. and at reduced pressure for more than 8 hours.

4. A process according to claim 3, in which said ondansetron hydrochloride dihydrate is desolvated by heating at a temperature of about 50.degree. C. at a pressure of about 100 torr for about 24 hours.

5. A process according to claim 1, in which said ondansetron hydrochloride dihydrate is desolvated by heating at a temperature of 50.degree. C. or above at ambient pressure.

6. A process according to claim 5, in which said temperature is about 100.degree. C.

7. A process according to claim 1, in which said ondansetron hydrochloride dihydrate is rehydrated in a humidified atmosphere at ambient temperature.

8. A process for reducing the crystal size of ondansetron hydrochloride dihydrate produced by crystallisation from solvent, in which said ondansetron hydrochloride dihydrate is desolvated by drying at elevated temperature and reduced or atmospheric pressure and is then rehydrated, wherein the resulting crystals are suitable for effective distribution in a tablet blend, said tablet providing a pharmaceutically acceptable formulation in effective amounts for treatment of ondansetron responsive conditions.

9. A process according to claim 8, in which said ondansetron hydrochloride dihydrate is prepared by crystallisation from an aqueous solvent mixture.

10. A process according to claim 8, in which said ondandsetron hydrochloride dihydrate is desolvated by heating at a temperature greater than 40.degree. C. and at reduced pressure for more than 8 hours.

11. A process according to claim 10, in which said ondansetron hydrochloride dihydrate is desolvated by heating at a temperature of about 50.degree. C. at a pressure of about 100 torr for about 24 hours.

12. A process according to claim 8, in which said ondansetron hydrochloride dihydrate is desolvated by heating at a temperature of 50.degree. C. or above at ambient pressure.

13. A process according to claim 12, in which said temperature is about 100.degree. C.

14. A process according to claim 8, in which said ondansetron hydrochloride dihydrate is rehydrated in a humidified atmosphere at ambient temperature.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc